Aug 17, 2013

Apple Giovanni Ferrara from Burrill & Company is a member of FundingPost online! Venture Fund Member Profile Share This Profile: Burrill & Company is a life sciences merchant bank focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses) with over $500 million under management. Burrill's technical and venture investing competence spans the entire spectrum of life sciences. The expertise of the firm's investment team, strategic partners and Advisory Boards is unparalleled in depth and breadth. In addition, Burrill is a leader in life science strategic partnering, an invaluable practice to build value in portfolio companies and to accelerate their growth and development. Giovanni Ferrara Managing Director Burrill & Company Prior to joining Burrill & Company, Mr. Ferrara was Manager at GeneChem Management, Inc., a healthcare venture capital firm, where he led several syndicated investments in Canada and the United States. He also held interim operating positions in portfolio companies and worked closely with BioChem Pharma's CSO and business development team in sourcing and pursuing inlicensing opportunities, which led to two of BioChem's largest deals, having achieved approximately $95 million in business development transactions. Prior to joining the venture capital community, he was a financial analyst at Letko, Brosseau & Associates. He began his career in healthcare as a pharmacist at a private cancer treatment center in Toronto focusing on experimental therapies. Representative Investments Adlyfe is a company that is developing screening and diagnostic products based upon its misfolded-protein detection (MPD) platform. The Company is developing its MPD Platform technology to produce simple, highly sensitive, low-cost and rapid-action test kits for the blood screening, human diagnostics and animal testing markets. The Company is currently working on the following programs: TSE-Pronucleon, to enable rapid and accurate testing of human blood units for vCJD and AD-Pronucleon an MPD Platform-based assay for early diagnosis of Alzheimer’s disease (AD). CardioKine develops pharmaceuticals for the treatment and prevention of heart failure and related cardiovascular indications. Their initial product, Lixivaptan, an electrolyte-sparing diuretic, was licensed from Wyeth. Corazonas offers snacks that are formulated using ingredients that are scientifically proven to help maintain heart health. The first offering in the Corazonas platform is heart healthy tortilla chips, formulated using whole oats and plant sterols, with no trans fats, reduced sodium and virtually no saturated fat. Dreamerz has developed an all natural sleep aid beverage. Dreamerz beverage contains based product targeted to the quality of sleep market. About FundingPost For over Fourteen Years FundingPost has worked with thousandsof Angel and Venture Capital Investors. We believe that it isimportant to reach investors in every medium possible -both online and offline. We have been directly responsible fortons of success stories and Millions and Millions of dollars raised.We look forward to introducing your company to the leading Venture and Angel Investors nationwide. Sign up now: Entrepreneurs / Investors Join the FundingPost email list and learn how, when and where you can meet these Investors: Other Venture Profiles: